The FDA has approved nelarabine for injection (SH-111) for the treatment of patients with T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL), providing patients with an alternative to a treatment that has historically been in shortage, according to an announcement from Shorla Oncology.
Read more at:
https://www.onclive.com/view/fda-approves-nelarabine-injection-for-t-cell-leukemia-and-lymphoma
